Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $2.9MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Zebra Aggregator, Lp | Affiliate | Aug 19 '26 | Proposed Sale | $31.91 | 1,000,000 | $31,910,000 | — | Aug 19 04:15 PM |
| Moulder Leon O Jr | Chief Executive Officer | May 18 '26 | Buy | $16.88 | 60,000 | $1,012,800 | 96,928 | May 18 09:12 PM |
| Moulder Leon O Jr | Chief Executive Officer | Apr 29 '26 | Buy | $17.62 | 35,000 | $616,700 | 1,786,039 | Apr 29 07:21 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.